Note: Where available, the PDF/Word icon below is provided to view the complete and fully formatted document
 Download PDFDownload PDF 

Previous Fragment    Next Fragment
Community Affairs Legislation Committee
Office of the Gene Technology Regulator

Office of the Gene Technology Regulator

[14:0 8 ]

CHAIR: Welcome.

Senator FIERRAVANTI-WELLS: Like TGA, you are in the circumstance that your funding and expenses are included in the overall budget statement. Is that the case?

Dr Smith : Yes.

Senator FIERRAVANTI-WELLS: I am looking at program 1.4. Your component is $8,179 million, there at page 49?

Dr Smith : Yes.

Senator FIERRAVANTI-WELLS: Would the figure for 2010-11 be reflected in the annual report?

Dr Smith : Yes.

Senator FIERRAVANTI-WELLS: Do you have that figure, perchance?

Dr Smith : I have the figures here, but they are without GST components. I can give you the total expenses for those years: $7.889 million for 2010-11 and $8.158 million for 2011-12.

Senator FIERRAVANTI-WELLS: And what about for 2012-13? Are you on track?

Dr Smith : Yes, we are on track to break even.

Senator FIERRAVANTI-WELLS: Ms Halton, you have a very good record here. They all seem to be on track!

Ms Halton : Are you surprised, Senator?

Senator FIERRAVANTI-WELLS: No, I am not! So, there have been no changes to your budget since the PBS?

Dr Smith : No.

Senator FIERRAVANTI-WELLS: Has there been any variation in staff numbers?

Dr Smith : Not from what is in the budget.

Senator FIERRAVANTI-WELLS: And are you on track in relation to forward estimates?

Dr Smith : We are on track as best as we can predict, yes.

Senator FIERRAVANTI-WELLS: Thank you. That is all I have.

CHAIR: I believe Senator Siewert may have some questions on notice. Thank you very much.